ReviewPathology oncology research : POR2001
Molecular genetic abnormalities in the pathogenesis of human lung cancer.
Review in Pathology oncology research : POR, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Deciphering DNA repair gene mutational landscape in uterine corpus endometrial carcinoma patients using next generation sequencing.American journal of cancer research · 2024Article
- A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease.Life (Basel, Switzerland) · 2022Review
- Id2 exerts tumor suppressor properties in lung cancer through its effects on cancer cell invasion and migration.Frontiers in oncology · 2022Article
- Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients.Experimental and therapeutic medicine · 2013Article
- The Biological Role of PI3K Pathway in Lung Cancer.Pharmaceuticals (Basel, Switzerland) · 2012Article
- Interphase cytogenetics of sputum cells for the early detection of lung carcinogenesis.Cancer prevention research (Philadelphia, Pa.) · 2010Review
- Targeting the eicosanoid pathway in non-small-cell lung cancer.Expert opinion on therapeutic targets · 2009Review
- Decreased TIP30 expression promotes tumor metastasis in lung cancer.The American journal of pathology · 2009Article
- [Small cell lung cancer: pathology and molecular pathology].Der Pathologe · 2009Article
- Association of progressive structural changes in the bronchial epithelium with subepithelial fibrous remodeling: a potential role for hypoxia.Virchows Archiv : an international journal of pathology · 2007Article
- FRMD3, a novel putative tumour suppressor in NSCLC.Oncogene · 2007Article
- [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].Wiener klinische Wochenschrift · 2007Review
- Analysis of epidemiological cohort data on smoking effects and lung cancer with a multi-stage cancer model.Carcinogenesis · 2006Article
- Oncogenes come of age.Cold Spring Harbor symposia on quantitative biology · 2005Review
- pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis.Oncogene · 2003Article
- Clinical impact of novel treatment strategies.Oncogene · 2002Review
- Molecular characteristics of non-small cell lung cancer.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.Genes & development · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the past few years our knowledge of the molecular pathogenesis of lung cancer has significantly increased. There are several molecular mechanisms involved in the multistage carcinogenesis through which respiratory epithelial cells become preneoplastic and then invasive cancer. In this review we summarize some of these changes including, genomic alterations such as loss of heterozygosity and microsatellite alterations, autocrine-paracrine loops, alterations in oncogenes and tumor suppressor genes, tumor angiogenesis, aberrant promoter methylation and inherited predisposition to lung cancer. Translation of these findings to the clinic is also discussed.
Indexed as
Identifiers
11349214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.